BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35092378)

  • 1. TP53 and EGFR Mutational Status in Thymoma: A Genetic Sequencing Study.
    Syahruddin E; Zaini J; Sembiring R; Baginta R; Fadhillah MR; Noor DR
    Asian Pac J Cancer Prev; 2022 Jan; 23(1):109-114. PubMed ID: 35092378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3.
    Sakane T; Murase T; Okuda K; Saida K; Masaki A; Yamada T; Saito Y; Nakanishi R; Inagaki H
    Histopathology; 2019 Nov; 75(5):755-766. PubMed ID: 31179560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
    Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
    Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of TP53 mutations in benign and malignant salivary gland neoplasms.
    Gomes CC; Diniz MG; Orsine LA; Duarte AP; Fonseca-Silva T; Conn BI; De Marco L; Pereira CM; Gomez RS
    PLoS One; 2012; 7(7):e41261. PubMed ID: 22829934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation analysis of the EGFR gene and its downstream signaling pathway in thymic carcinoma patients from a Chinese Han population.
    Zhan P; Chen X; Wu XY; Hou ZB; Qian Q; Zhang Y; Zou J; Zhang YQ; Wan MY; Wang JD; Yu LK; Xie HY
    Clin Respir J; 2018 Feb; 12(2):601-607. PubMed ID: 27731926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors.
    Suzuki E; Sasaki H; Kawano O; Endo K; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Jpn J Clin Oncol; 2006 Jun; 36(6):351-6. PubMed ID: 16762968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis.
    Moreira AL; Won HH; McMillan R; Huang J; Riely GJ; Ladanyi M; Berger MF
    J Thorac Oncol; 2015 Feb; 10(2):373-80. PubMed ID: 25299233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
    Jiao XD; Qin BD; You P; Cai J; Zang YS
    Lung Cancer; 2018 Sep; 123():70-75. PubMed ID: 30089598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.
    Zhao Y; Pan Y; Cheng C; Zheng D; Zhang Y; Gao Z; Fu F; Li H; Zheng S; Zhuge L; Mao H; Kuang M; Tao X; Peng Y; Hu H; Xiang J; Li Y; Sun Y; Chen H
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1781-1789. PubMed ID: 32361787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High resolution melting for mutation scanning of TP53 exons 5-8.
    Krypuy M; Ahmed AA; Etemadmoghadam D; Hyland SJ; ; DeFazio A; Fox SB; Brenton JD; Bowtell DD; Dobrovic A
    BMC Cancer; 2007 Aug; 7():168. PubMed ID: 17764544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).
    Li XM; Li WF; Lin JT; Yan HH; Tu HY; Chen HJ; Wang BC; Wang Z; Zhou Q; Zhang XC; Su J; Chen RL; Wu YL; Yang JJ
    Clin Lung Cancer; 2021 Mar; 22(2):100-109.e3. PubMed ID: 33317922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymoma associated with malignancies may herald a hereditary cancer syndrome.
    Tehrani OS; Chen EQ; Schaebler DL; Mughal AW
    Fam Cancer; 2010 Dec; 9(4):655-7. PubMed ID: 20734236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
    Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
    Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers.
    Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY
    Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
    Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete remission following icotinib administration in an advanced ectopic thymic carcinoma patient harbouring the EGFR exon 19 deletion.
    Zu Y; Luo Y; Li C; Zhao J; He T; Shi X; Li X
    J Gene Med; 2021 Jul; 23(7):e3340. PubMed ID: 33835620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas.
    Meister M; Schirmacher P; Dienemann H; Mechtersheimer G; Schnabel PA; Kern MA; Herpel E; Xu EC; Muley T; Thomas M; Rieker RJ
    Cancer Lett; 2007 Apr; 248(2):186-91. PubMed ID: 16919868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma.
    Hirabayashi H; Fujii Y; Sakaguchi M; Tanaka H; Yoon HE; Komoto Y; Inoue M; Miyoshi S; Matsuda H
    Int J Cancer; 1997 Nov; 73(5):639-44. PubMed ID: 9398039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
    Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma.
    Liu DH; Zhao ZR; Lin YB; Zhou WJ; Hou JY; Ye ZH; Long H
    Ann Surg Oncol; 2019 Jun; 26(6):1934-1941. PubMed ID: 30820786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.